Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland

Transfusion Medicine and Hemotherapy

Volumn 45, Issue 3, 2018, Pages 151-156

  Jutzi, Markus ^a   Mansouri Taleghani, Behrouz ^b   Rueesch, Morven ^c   Amsler, Lorenz ^d   Buser, Andreas ^e  

^a Blood Transfusion Service SRC Berne   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Blood Transfusion Service   (Switzerland)

^d Division of Internal Medicine   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Blood safety; Platelet concentrates; Transfusion reaction; Transfusion risks; Transfusion associated infections

Indexed keywords

NONOXINOL 9; THROMBOCYTE CONCENTRATE;

ARTICLE; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; BLOOD STORAGE; CLINICAL EVALUATION; COMPARATIVE STUDY; HEALTH CARE PLANNING; HEMATOLOGICAL PROCEDURE; HUMAN; MORBIDITY; MORTALITY RATE; PATHOGEN INACTIVATION; QUALITY CONTROL PROCEDURES; RISK FACTOR; SWITZERLAND; THROMBOCYTE TRANSFUSION;

EID: 85047415487     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000489900     Document Type: Article

References (35)

1. Ramirez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M: Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion 2007; 47: 421-429
2. Brecher ME, Hay SN: Bacterial contamination of blood components. Clin Microbiol Rev 2005; 18: 195-204.
3. Blajchman MA, Beckers EA, Dickmeiss E, Lin L, Moore G, Muylle L: Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005; 19: 259-272.
4. Swissmedic Haemovigilance Annual Reports (Report 2009). www. swissmedic. ch/swissmedic/de/home/humanarzneimittel/ marktueberwachung/haemovigilance/ publications. html (last accessed May 9, 2018).
5. Swissmedic, Authorised Procedures. /www. swissmedic. ch/swissmedic/de/home/services/zugelassene-verfahrenund-wirkstoffe. html (last accessed May 9, 2018).
6. Irsch J, Lin L: Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood SystemTM. Transfus Med Hemother 2011; 38: 19-31.
7. Osselaer JC, Cazenave JP, Lambermont M. Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L: An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315-323.
8. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L: A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061-1071.
9. Cid J, Escolar G, Lozano M: Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012; 103; 322-330.
10. Vamvakas EC: Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system Vox Sang 2012; 102: 302-316.
11. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-1541.
12. Corash, L, Lin JS, Sherman CD, Eiden J: Determination of acute lung injury after repeated platelet transfusions. Blood 2011; 117: 1014-1020.
13. Gelderman, MP, Chi X, Zhi L, Vostal JG: Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion. Transfusion 2011; 51: 2343-2357.
14. Kerkhoffs JH, Novotny PA, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus L, van Putten WL, Huijgens PC, Brand A, van Rhenen DJ: Clinical effectiveness and safety of pooled, random donor platelet concentrates, leukoreduced and stored up to seven days in either plasma or additive solution with and without pathogen reduction in hemato-oncological patients. AABB Annual Assembly, 2009, Abstract Book P5-020A.
15. Ciaravino V, McCullough T, Cimino G: The role of toxicology assessment in transfusion medicine. Transfusion 2003; 43: 1481-1492.
16. Swissmedic Haemovigilance Annual Reports (Report 2015). www. swissmedic. ch/dam/swissmedic/en/dokumente/ marktueberwachung/haemovigilance/haemovigilance- jahresbericht2015. pdf. download. pdf/haemovigilance- annualreport2015. pdf (last accessed May 9, 2018).
17. Presentation of Swiss Haemovigilance Data. www. swissmedic. ch/dam/swissmedic/en/dokumente/marktueberwachung/ haemovigilance/pathogeninaktivierungplaettcheneinfuehrungundklinischeauswirkung. pdf. download. pdf/pathogeninaktivierungplaettcheneinfuehrungundklinischeauswirkung. pdf (last accessed May 9, 2018).
18. French Haemovigilance Annual Reports. http://ansm. sante. fr/Mediatheque/Publications/Bilans-Rapports-dactivite-Bilans-et-rapports-d-activite (last accessed May 9, 2018).
19. Andreu G, Caldani C, Morel P: Reduction of septic transfusion reactions related to bacteria contamination without implementing bacteria detection. ISBT Sci Ser 2008; 3: 124-132.
20. Global Status Report on Blood Safety and Availability 2016. http://apps. who. int/iris/handle/10665/254987 (last accessed May 9, 2018).
21. SHOT Annual Reports8. www. shotuk. org/shot-reports/ (last accessed May 9, 2018).
22. Te Boekhorst PAW, Beckers EAM, Vos MC, Vermeij H, Van Rhenen DJ: Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005; 45: 514-519.
23. Kleinman S, Dumont LJ, Tomasulo P, Bianco C, Katz L, Benjamin RJ, Gajic O, Brecher ME: The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion 2009; 49: 903-912.
24. Dumont LJ, Kleinman S, Murphy JR, Lippincott R, Schuyler R, Houghton M, Metzel P: Blood components: screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010; 50: 589-599.
25. Pearce S, Rowe GP, Field SP: Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfus Med 2011; 21: 25-32.
26. Jenkins C, Ramirez-Arcos S, Goldman M, Devine DV: Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk Transfusion 2011; 51: 2555-2565.
27. De Korte D, de Kort WLAM, Hoekstra T, van der Poel CL, Beckers EAM, Marcelis JH: Effects of skin disinfection method, deviation bag and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006; 46: 476-485.
28. Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ: Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007; 47: 1134-1142.
29. Eder AF, Kennedy JM, Dy BA, Notari EP, Skeate R, Bachowski G, Mair DC, Webb JS, Wagner SJ, Dodd RY, Benjamin RJ: Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49: 1554-1563.
30. Ramirez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M: Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion 2007; 47: 421-429.
31. Schrezenmeier H, Walther-Wenke G, Muller TH, Weinauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, Deitenbeck R, Forstemann E, Gebauer W, Hochsmann B, Karakassopoulos A, Liebscher U-M, Sanger W, Schmidt M, Schunter F, Sireis W, Seifried E: Bacterial contamination of platelet concentrates: results of a prospective multicentre study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47: 644-652.
32. Custer B, Agapova M, Havlir Martinez R: The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010; 50: 2461-2473.
33. Bell CE, Botterman MF, Gao X, Weissfeld JL, Maarten JP, Pashos CL, Triulzi, D, Staginnus U: Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003; 25: 2464-2486.
34. Davidson T, Ekermo B, Gaines H, Lesko B, Akerlind B: The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. Transfusion 2011; 51: 421-429.
35. FDA News Release. https://wayback. archive-it. org/ 7993/20170111092906/http://www. fda. gov/NewsEvents/ Newsroom/PressAnnouncements/ucm427500. htm (last accessed May 9, 2018).